Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Investment Partners LTD.

Investment Partners LTD. decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% in the 4th quarter, Holdings Channel reports. The firm owned 1,497 shares of the medical research company’s stock after selling 99 shares during the quarter. Investment Partners LTD.’s holdings in Thermo Fisher Scientific were worth $794,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Strategic Blueprint LLC raised its position in Thermo Fisher Scientific by 7.8% during the third quarter. Strategic Blueprint LLC now owns 1,124 shares of the medical research company’s stock worth $569,000 after acquiring an additional 81 shares during the last quarter. Apeiron RIA LLC raised its position in Thermo Fisher Scientific by 4.8% during the third quarter. Apeiron RIA LLC now owns 671 shares of the medical research company’s stock worth $340,000 after acquiring an additional 31 shares during the last quarter. First Personal Financial Services raised its position in Thermo Fisher Scientific by 1.9% during the third quarter. First Personal Financial Services now owns 19,621 shares of the medical research company’s stock worth $9,932,000 after acquiring an additional 359 shares during the last quarter. MCF Advisors LLC raised its position in Thermo Fisher Scientific by 59.7% during the third quarter. MCF Advisors LLC now owns 1,817 shares of the medical research company’s stock worth $920,000 after acquiring an additional 679 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 2.1% during the third quarter. U.S. Capital Wealth Advisors LLC now owns 8,606 shares of the medical research company’s stock worth $4,356,000 after buying an additional 175 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.3 %

TMO stock traded up $1.87 during midday trading on Friday, reaching $573.60. 1,438,184 shares of the company’s stock traded hands, compared to its average volume of 1,317,052. The company has a market capitalization of $218.95 billion, a P/E ratio of 36.79, a PEG ratio of 2.41 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The business has a 50-day moving average price of $573.60 and a two-hundred day moving average price of $529.90.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.54 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 5,547 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the completion of the sale, the chief executive officer now directly owns 43,608 shares in the company, valued at $24,011,436.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock valued at $28,513,384. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on TMO. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday. Evercore ISI lifted their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. HSBC lifted their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Finally, Barclays boosted their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $606.76.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.